Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

SOUTH SAN FRANCISCO, Calif., December 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating ...

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits ...

I hope to see you there. Analyst’s Disclosure: I/we have a beneficial long position in the shares of RHHBY either through stock ownership, options, or other derivatives. I wrote this article ...

AbbVie ABBV announced that the FDA has granted a Breakthrough Therapy Designation (BTD) to its investigational antibody-drug conjugate (ADC) telisotuzumab vedotin ...

The FDA accepts Roche's (OTCQX:RHHBY) supplemental New Drug Application (sNDA) seeking approval for Alecensa (alectinib) for the first-line treatment of anaplastic ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Roche RHHBY-partnered Venclexta sales are likely ... Let us delve deeper to understand whether to buy, sell or hold the stock. Shares of AbbVie have risen nearly 8% in the past year against ...